{"classes":[{"categories":[{"measurements":[{"comment":"NA means not achieved or not estimable.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"For subjects who achieved an NIH-defined CR or PR, the interval between the date of initial documentation of a response and the date of first documented evidence of PD, death, or date of censoring if applicable.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects receive daily dose of 420 mg of Ibrutinib capsules","id":"OG000","title":"Phase1b/Phase 2"}],"paramType":"MEDIAN","populationDescription":"Phase 2 subjects includes all subjects who participated in Phase 1b","reportingStatus":"POSTED","timeFrame":"Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.","title":"To Evaluate the Clinical Efficacy of Ibrutinib in Steroid Dependent/Refractory cGVHD by Measuring: Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Median"}